I wrote a bit about clinical trials here: How do you pick which clinical trials to join?
hu3F8 is still just in Phase 2. So we know what dosages we can give, and we can measure there is a lot of antibody in the blood. But… it is going to take another 5 years until long term studies are published.
MSK have graphs that they share yearly and the graphs they share comparing 3F8 to hu3F8 always show a marked improvement when they introduced hu3F8.
ch14.18 is quite an intense experience, involving a week plus of hospitalization (for standard non long term infusion). hu3F8 in comparison is a day visit to the hospital and a 1 hour infusion after which you go home.
The big ray of light here is that an international trial is in progress: Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow - Full Text View - ClinicalTrials.gov